Friday, October 2, 2026
26.3 C
Bengaluru

Pharma and the Covid19 Crisis – An Interaction with Sunil Attavar, CMD, Group Pharma

This is the first part of MedicinMan interview series with pharma business leaders to make sense of the Covid19 crisis and its impact on healthcare industry. Subscribe to MedicinMan to get regular updates of interactions with pharma business leaders.

MedicinMan: Give our readers, a sense of what is happening in the pharma industry since the corona virus outbreak. What are the main areas of impact? How are Indian Pharma leaders responding to these challenges and what are the timelines that they are looking at in terms of the current situation?

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Shakul Srivastava has been appointed as Senior Vice President at Indian Immunologicals Limited.

With over three decades of experience in the pharmaceutical...

The Rx–Outcomes Dichotomy: India Has Iron Tablets. Why Does Anaemia Persist?

India’s anaemia challenge is not simply about access to...

10 Years of Pharma M&A — Who’s Really Benefited?

Pharmaceutical M&A is usually discussed in the language of...

What’s Killing Patients? Cancer or Rigged Drug Prices?

The disease is real. So is the markup. Confusing...

A Tale of Two Cities: Peptides and Prescriptions

What our health choices reveal about education, access and...

Topics

spot_img

Related Articles

spot_imgspot_img